Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.

Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Varešlija D, Chin SF, Linn SC, Young LS, Jirström K, Crown J, Bernards R, Caldas C, Gallagher WM, O'Connor DP, Ni Chonghaile T.

Clin Cancer Res. 2019 Aug 13. pii: clincanres.0713.2019. doi: 10.1158/1078-0432.CCR-19-0713. [Epub ahead of print]

PMID:
31409615
2.

Altered steroid milieu in AI resistant breast cancer facilitates AR mediated gene expression associated with poor response to therapy.

Creevey L, Bleach R, Madden SF, Toomey S, Bane FT, Varešlija D, Hill AD, Young LS, McIlroy M.

Mol Cancer Ther. 2019 Jul 9. pii: molcanther.0791.2018. doi: 10.1158/1535-7163.MCT-18-0791. [Epub ahead of print]

PMID:
31289138
3.

MicroRNA-22 Controls Aberrant Neurogenesis and Changes in Neuronal Morphology After Status Epilepticus.

Beamer EH, Jurado-Arjona J, Jimenez-Mateos EM, Morgan J, Reschke CR, Kenny A, de Leo G, Olivos-Oré LA, Arribas-Blázquez M, Madden SF, Merchán-Rubira J, Delanty N, Farrell MA, O'Brien DF, Avila J, Diaz-Hernandez M, Miras-Portugal MT, Artalejo AR, Hernandez F, Henshall DC, Engel T.

Front Mol Neurosci. 2018 Dec 11;11:442. doi: 10.3389/fnmol.2018.00442. eCollection 2018.

4.

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J.

BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1.

5.

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells.

Synnott NC, Madden SF, Bykov VJN, Crown J, Wiman KG, Duffy MJ.

Transl Oncol. 2018 Dec;11(6):1343-1349. doi: 10.1016/j.tranon.2018.08.009. Epub 2018 Sep 6.

6.

Complex spectrum of phenobarbital effects in a mouse model of neonatal hypoxia-induced seizures.

Quinlan SMM, Rodriguez-Alvarez N, Molloy EJ, Madden SF, Boylan GB, Henshall DC, Jimenez-Mateos EM.

Sci Rep. 2018 Jul 3;8(1):9986. doi: 10.1038/s41598-018-28044-2.

7.

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.

Milewska M, Cremona M, Morgan C, O'Shea J, Carr A, Vellanki SH, Hopkins AM, Toomey S, Madden SF, Hennessy BT, Eustace AJ.

Ther Adv Med Oncol. 2018 Jan 9;10:1758834017746040. doi: 10.1177/1758834017746040. eCollection 2018.

8.

Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer.

Muliaditan T, Opzoomer JW, Caron J, Okesola M, Kosti P, Lall S, Van Hemelrijck M, Dazzi F, Tutt A, Grigoriadis A, Gillett CE, Madden SF, Burchell JM, Kordasti S, Diebold SS, Spicer JF, Arnold JN.

Clin Cancer Res. 2018 Apr 1;24(7):1617-1628. doi: 10.1158/1078-0432.CCR-17-2587. Epub 2018 Jan 16.

9.

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.

O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ.

Oncotarget. 2017 Jul 22;8(49):85120-85135. doi: 10.18632/oncotarget.19461. eCollection 2017 Oct 17.

10.

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.

Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.

11.

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.

Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O'Byrne KJ, O'Donovan N, Crown J.

Cell Immunol. 2017 Sep;319:35-42. doi: 10.1016/j.cellimm.2017.07.005. Epub 2017 Jul 15.

PMID:
28735814
12.

Expression of anaesthetic and analgesic drug target genes in excised breast tumour tissue: Association with clinical disease recurrence or metastasis.

Connolly C, Madden SF, Buggy DJ, Gallagher HC.

PLoS One. 2017 May 30;12(5):e0177105. doi: 10.1371/journal.pone.0177105. eCollection 2017.

13.

Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.

McDermott MSJ, Canonici A, Ivers L, Browne BC, Madden SF, O'Brien NA, Crown J, O'Donovan N.

Int J Oncol. 2017 Jun;50(6):2221-2228. doi: 10.3892/ijo.2017.3976. Epub 2017 Apr 26.

PMID:
28498399
14.

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

Li B, Ni Chonghaile T, Fan Y, Madden SF, Klinger R, O'Connor AE, Walsh L, O'Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn S, Jirstrom K, Caldas C, O'Connor DP, Gallagher WM.

Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28.

15.

Bidirectional KCNQ1:β-catenin interaction drives colorectal cancer cell differentiation.

Rapetti-Mauss R, Bustos V, Thomas W, McBryan J, Harvey H, Lajczak N, Madden SF, Pellissier B, Borgese F, Soriani O, Harvey BJ.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4159-4164. doi: 10.1073/pnas.1702913114. Epub 2017 Apr 3.

16.

The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.

Lundon DJ, Boland A, Prencipe M, Hurley G, O'Neill A, Kay E, Aherne ST, Doolan P, Madden SF, Clynes M, Morrissey C, Fitzpatrick JM, Watson RW.

BMC Cancer. 2017 Mar 1;17(1):163. doi: 10.1186/s12885-017-3100-4.

17.

Vitamin D receptor as a target for breast cancer therapy.

Murray A, Madden SF, Synnott NC, Klinger R, O'Connor D, O'Donovan N, Gallagher W, Crown J, Duffy MJ.

Endocr Relat Cancer. 2017 Apr;24(4):181-195. doi: 10.1530/ERC-16-0463. Epub 2017 Feb 17.

PMID:
28213567
18.

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.

Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ.

Oncotarget. 2016 Nov 15;7(46):75518-75525. doi: 10.18632/oncotarget.12782.

19.

Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.

Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O'Donovan N, Crown J, Duffy MJ.

Endocr Relat Cancer. 2016 Apr;23(4):323-34. doi: 10.1530/ERC-16-0068. Epub 2016 Mar 1.

PMID:
26932782
20.

ADAM10: a new player in breast cancer progression?

Mullooly M, McGowan PM, Kennedy SA, Madden SF, Crown J, O' Donovan N, Duffy MJ.

Br J Cancer. 2015 Sep 15;113(6):945-51. doi: 10.1038/bjc.2015.288. Epub 2015 Aug 18.

21.

Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients.

Lanigan F, Brien GL, Fan Y, Madden SF, Jerman E, Maratha A, Aloraifi F, Hokamp K, Dunne EJ, Lohan AJ, Flanagan L, Garbe JC, Stampfer MR, Fridberg M, Jirstrom K, Quinn CM, Loftus B, Gallagher WM, Geraghty J, Bracken AP.

FEBS J. 2015 Sep;282(18):3455-73. doi: 10.1111/febs.13354. Epub 2015 Jul 14.

22.

Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression.

Aherne ST, Madden SF, Hughes DJ, Pardini B, Naccarati A, Levy M, Vodicka P, Neary P, Dowling P, Clynes M.

BMC Cancer. 2015 Apr 30;15:329. doi: 10.1186/s12885-015-1327-5.

23.

Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.

Weiner-Gorzel K, Dempsey E, Milewska M, McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A, Sharpe D, O'Sullivan J, Murphy M, Madden SF, Kell M, McCann A, Furlong F.

Cancer Med. 2015 May;4(5):745-58. doi: 10.1002/cam4.409. Epub 2015 Feb 15.

24.

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.

Madden SF, Clarke C, Stordal B, Carey MS, Broaddus R, Gallagher WM, Crown J, Mills GB, Hennessy BT.

Mol Cancer. 2014 Oct 24;13:241. doi: 10.1186/1476-4598-13-241.

25.

Increase in sialylation and branching in the mouse serum N-glycome correlates with inflammation and ovarian tumour progression.

Saldova R, Piccard H, Pérez-Garay M, Harvey DJ, Struwe WB, Galligan MC, Berghmans N, Madden SF, Peracaula R, Opdenakker G, Rudd PM.

PLoS One. 2013 Aug 30;8(8):e71159. doi: 10.1371/journal.pone.0071159. eCollection 2013.

26.

BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome.

Madden SF, Clarke C, Gaule P, Aherne ST, O'Donovan N, Clynes M, Crown J, Gallagher WM.

Breast Cancer Res. 2013;15(4):R52.

27.

A gene expression profile indicative of early stage HER2 targeted therapy response.

O'Neill F, Madden SF, Clynes M, Crown J, Doolan P, Aherne ST, O'Connor R.

Mol Cancer. 2013 Jul 1;12:69. doi: 10.1186/1476-4598-12-69.

28.

Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis.

Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, Kennedy S, Clynes M.

Carcinogenesis. 2013 Oct;34(10):2300-8. doi: 10.1093/carcin/bgt208. Epub 2013 Jun 5.

PMID:
23740839
29.

Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.

O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM.

BMC Cancer. 2013 Apr 2;13:175. doi: 10.1186/1471-2407-13-175.

30.

Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target?

Prencipe M, Madden SF, O'Neill A, O'Hurley G, Culhane A, O'Connor D, Klocker H, Kay EW, Gallagher WM, Watson WR.

Prostate. 2013 May;73(7):743-53. doi: 10.1002/pros.22618. Epub 2013 Jan 28.

PMID:
23359479
31.

Integrated miRNA, mRNA and protein expression analysis reveals the role of post-transcriptional regulation in controlling CHO cell growth rate.

Clarke C, Henry M, Doolan P, Kelly S, Aherne S, Sanchez N, Kelly P, Kinsella P, Breen L, Madden SF, Zhang L, Leonard M, Clynes M, Meleady P, Barron N.

BMC Genomics. 2012 Nov 21;13:656. doi: 10.1186/1471-2164-13-656.

32.

miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.

Mulrane L, Madden SF, Brennan DJ, Gremel G, McGee SF, McNally S, Martin F, Crown JP, Jirström K, Higgins DG, Gallagher WM, O'Connor DP.

Clin Cancer Res. 2012 Dec 15;18(24):6702-13. doi: 10.1158/1078-0432.CCR-12-1420. Epub 2012 Oct 11.

33.

ADAM-17: a novel therapeutic target for triple negative breast cancer.

McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, Pierce A, McDermott EW, Crown J, O'Donovan N, Duffy MJ.

Ann Oncol. 2013 Feb;24(2):362-9. doi: 10.1093/annonc/mds279. Epub 2012 Sep 11. Erratum in: Ann Oncol. 2013 Aug;24(8):2199.

PMID:
22967992
34.

Gene expression analysis in prostate cancer: the importance of the endogenous control.

Vajda A, Marignol L, Barrett C, Madden SF, Lynch TH, Hollywood D, Perry AS.

Prostate. 2013 Mar;73(4):382-90. doi: 10.1002/pros.22578. Epub 2012 Aug 27.

PMID:
22926970
35.

Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.

O'Neill F, Madden SF, Aherne ST, Clynes M, Crown J, Doolan P, O'Connor R.

Mol Cancer. 2012 Jun 18;11:41. doi: 10.1186/1476-4598-11-41.

36.

Proteomic portrait of human breast cancer progression identifies novel prognostic markers.

Geiger T, Madden SF, Gallagher WM, Cox J, Mann M.

Cancer Res. 2012 May 1;72(9):2428-39. doi: 10.1158/0008-5472.CAN-11-3711. Epub 2012 Mar 13.

37.

Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.

Kinsella P, Howley R, Doolan P, Clarke C, Madden SF, Clynes M, Farrell M, Amberger-Murphy V.

Exp Cell Res. 2012 Mar 10;318(5):641-52. doi: 10.1016/j.yexcr.2012.01.014. Epub 2012 Jan 20.

PMID:
22285130
38.

CGCDB: a web-based resource for the investigation of gene coexpression in CHO cell culture.

Clarke C, Doolan P, Barron N, Meleady P, Madden SF, DiNino D, Leonard M, Clynes M.

Biotechnol Bioeng. 2012 Jun;109(6):1368-70. doi: 10.1002/bit.24416. Epub 2012 Jan 4.

PMID:
22189966
39.

5-AZA-2'-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer.

Saldova R, Dempsey E, Pérez-Garay M, Mariño K, Watson JA, Blanco-Fernández A, Struwe WB, Harvey DJ, Madden SF, Peracaula R, McCann A, Rudd PM.

Epigenetics. 2011 Nov;6(11):1362-72. doi: 10.4161/epi.6.11.17977. Epub 2011 Nov 1.

PMID:
22086115
40.

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM.

Cancer Discov. 2011 Jun;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028. Epub 2011 Jun 1.

41.

Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma.

Jennings CJ, O'Grady A, Cummins R, Murer B, Al-Alawi M, Madden SF, Mutti L, Harvey BJ, Thomas W, Kay EW.

J Thorac Oncol. 2012 Jan;7(1):243-8. doi: 10.1097/JTO.0b013e31822f6544.

42.

Detecting microRNA activity from gene expression data.

Madden SF, Carpenter SB, Jeffery IB, Björkbacka H, Fitzgerald KA, O'Neill LA, Higgins DG.

BMC Bioinformatics. 2010 May 18;11:257. doi: 10.1186/1471-2105-11-257.

43.

Hypoxia selectively activates the CREB family of transcription factors in the in vivo lung.

Leonard MO, Howell K, Madden SF, Costello CM, Higgins DG, Taylor CT, McLoughlin P.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):977-83. doi: 10.1164/rccm.200712-1890OC. Epub 2008 Aug 8.

44.

Distinct patterns in the regulation and evolution of human cancer genes.

Furney SJ, Madden SF, Kisiel TA, Higgins DG, Lopez-Bigas N.

In Silico Biol. 2008;8(1):33-46.

PMID:
18430988
45.

Integrating transcription factor binding site information with gene expression datasets.

Jeffery IB, Madden SF, McGettigan PA, Perrière G, Culhane AC, Higgins DG.

Bioinformatics. 2007 Feb 1;23(3):298-305. Epub 2006 Nov 24.

PMID:
17127681
46.

ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion.

Moss AC, Lawlor G, Murray D, Tighe D, Madden SF, Mulligan AM, Keane CO, Brady HR, Doran PP, MacMathuna P.

Biochem Biophys Res Commun. 2006 Jun 23;345(1):216-21. Epub 2006 Apr 27.

PMID:
16678123
47.

Comprehensive/tertiary care for headache: a 6-month outcome study.

Saper JR, Lake AE 3rd, Madden SF, Kreeger C.

Headache. 1999 Apr;39(4):249-63.

PMID:
15613222
48.

Digital extractor: analysis of digital differential display output.

Madden SF, O'Donovan B, Furney SJ, Brady HR, Silvestre G, Doran PP.

Bioinformatics. 2003 Aug 12;19(12):1594-5.

PMID:
12912848
49.

Comprehensive inpatient treatment for intractable migraine: a prospective long-term outcome study.

Lake AE 3rd, Saper JR, Madden SF, Kreeger C.

Headache. 1993 Feb;33(2):55-62.

PMID:
8458722

Supplemental Content

Loading ...
Support Center